CJC-1295 is not „illegal” in the sense of being an illicit street drug. It is, however, banned in professional sports under global anti-doping regulations. And it has never received approval as an actual medicine from any major drug regulator. These are three related but distinct facts that often get conflated. As legal and regulatory status can change and varies significantly by country, this article reflects the most current information available. It also clearly flags where the picture is still unresolved or actively shifting.
Why is CJC-1295 banned?
CJC-1295 is explicitly listed as a prohibited substance on the World Anti-Doping Agency's (WADA) Prohibited List. It is categorized under S2, which covers peptide hormones, growth factors, and related substances. Specifically, it falls under the subsection of Growth Hormone Releasing Hormone (GHRH) analogs, alongside related compounds such as sermorelin and tesamoren [1]. This prohibition applies both in-competition and out-of-competition. There is no „off-season” period during which a tested athlete can use it and remain compliant.
The justification for this classification stems from the fundamental mechanism of CJC-1295. WADA prohibits substances that meet specific criteria: potential for performance enhancement, potential health risks, or conflict with the broader spirit of fair competition. A compound designed to durably elevate growth hormone and IGF-1 – as has been demonstrated for CJC-1295 in human trials – fits squarely within the type of substance these frameworks are built for [2].
Outside of sports, „contraband” is a less precise word to use. CJC-1295 is not classified as a controlled substance under US drug classification regulations. A more accurate regulatory description is that it has never completed the clinical trial and approval process required for the FDA or any comparable regulator to authorize it as a marketable drug. This is a different legal status than being listed as an illegal narcotic.
Is CJC-1295 legal in Europe?
The legal status of CJC-1295 varies significantly among European countries. This is an area where the regulatory landscape can change, so readers should verify current regulations with their own national health authority rather than relying solely on this summary.
In several European countries, including Germany, France, the Netherlands, Sweden, Norway, Denmark, and Spain, it has been reported that CJC-1295 requires a valid prescription for legal access. This is typically obtained through a licensed physician operating within the country's drug regulations, and it is not available over-the-counter or without medical involvement [3].
Specifically in the UK, regulatory guidance has described CJC-1295 as not having current marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). This means its unauthorised supply for human use falls outside the Human Medicines Regulations 2012. UK Anti-Doping (UKAD) also applies the same WADA-described prohibition above to any athlete subject to its testing programs [4].
Across the European Union more broadly, the general pattern holds. CJC-1295 has not received marketing authorization from the European Medicines Agency (EMA) for any indication. This means it does not hold the same legal standing as an approved prescription medicine within EU member states – even in countries where a physician might still prescribe it through other regulatory avenues, such as compounding arrangements.
Because regulations differ by country and are constantly evolving, this article does not offer country-specific purchasing advice. Any individual with questions about their situation should consult their national drug regulator or a licensed healthcare provider directly.
Is CJC-1295 FDA approved?
CJC-1295 is not approved by the FDA for any medical use. There is no completed New Drug Application or equivalent approval for it in the United States.
The history of its development helps explain why. Early-stage human studies in the mid-2000s showed that it could raise growth hormone and IGF-1 levels [5]. However, a subsequent Phase 2 clinical trial specifically testing it in HIV-associated visceral obesity patients was not completed. Development of the compound as a finished pharmaceutical product appears to have been halted rather than carried through the full approval process [6].
Separately from full drug approval, the FDA also maintains regulations regarding which „bulk drug substances” compounding pharmacies can prepare for patient-specific prescriptions under Section 503A of federal law. This classification for CJC-1295 compounding was reportedly subject to change during 2026. Some sources describe regulatory changes and an ongoing pending review process.
Because this particular drug classification is actively under review as of this writing, and various sources describe the situation slightly differently, this article does not state one definitive drug status here. Readers needing a precise, up-to-date answer should check the FDA's own published lists of bulk drug substances directly at fda.gov. This is the authoritative source, and the situation may have changed since this article was written.
It can be stated with certainty: CJC-1295 has never been a finished medicinal product approved by the FDA. It is not legally sold as a dietary supplement. And it remains, at minimum, a research compound from the perspective of federal drug approval.
How long is CJC-1295 detectable in urine?
Anti-doping laboratories have developed analytical methods capable of detecting CJC-1295 in urine at very low concentrations. This is important background for understanding detection windows, although the exact number of days an individual would test positive depends on factors such as dosage and individual metabolism – details that cannot be reduced to a single universal number.
A peer-reviewed analytical chemistry study developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. This method could detect CJC-1295 and several related GHRH analogs in spiked urine at concentrations at or below the WADA required limit of performance of 1 nanogram per milliliter. The researchers built this method on a detailed analysis of the compound's in vitro metabolites [7].
This type of sensitivity means that the detection technology for CJC-1295 is truly advanced and continues to improve. Separate anti-doping studies in veterinary medicine have developed immuno-PCR based tests capable of detecting CJC-1295 protein conjugates in horse plasma, down to 0.8 picograms per milliliter. This illustrates how low concentrations modern testing can identify [8].
It is worth noting, however, that the reviewed literature examined for this article does not specify a single, universal „detection window” measured in days for CJC-1295 in humans. The actual excretion time depends on several factors: the dose administered, whether a long-acting form bound with DAC or a shorter-acting form without DAC was used, and individual metabolic differences. This means that any specific number of days presented elsewhere as a hard rule should be treated with some caution, rather than as an exact, universally applicable figure.
Limitations of current evidence
The most definitive and stable fact across all sources reviewed here is the WADA ban on CJC-1295. This is well-documented and consistent.
The FDA's compounding classification, however, is presented differently across various sources at the time of writing. This truly reflects an unsettled and actively reviewed regulatory landscape, rather than a stable, agreed-upon fact. This article intentionally avoids stating one definitive number when primary sources disagree or when an official review is still ongoing.
Similarly, European legal status at the national level can vary and change. The detectability window figures for anti-doping testing also depend on variables not captured by a single number.
Disclaimer
This content is for educational and informational purposes only and should not be interpreted as legal advice. Legal regulations regarding research chemicals vary by country and change over time, and the information herein reflects the most current available understanding at the time of writing. CJC-1295 is not approved by the FDA or the European Medicines Agency for any medical use. Its status under anti-doping regulations, including the World Anti-Doping Agency (WADA), and its prescription or compounded status in any given country, should be independently verified with the appropriate regulatory body prior to use. This content does not constitute legal or medical advice. Any individual with questions regarding the legal status of CJC-1295 in their jurisdiction should consult with qualified legal counsel.
References
World Anti-Doping Agency. (2025). The Prohibited List. https://www.wada-ama.org/en/prohibited-list
[2] Memdouh, S., Gavrilović, I., Ng, K., Cowan, D., & Abbate, V. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis, 13(11–12), 1871–1887. https://doi.org/10.1002/dta.3183
peptide.law. (2026, February 28). Is CJC-1295 legal? Status in 158 countries (2026). https://peptide.law/peptides/cjc-1295
Bolt Pharmacy. (2026, May 21). CJC 1295, Ipamorelin, and Retatrutide: A UK Safety and Legal Guide. https://www.boltpharmacy.co.uk/guide/cjc-1295-ipamorelin-retatrutide
[5] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[6] National Center for Biotechnology Information. (2026). PubChem Compound Summary for CID 91971820, CJC-1295 [Clinical trial data: NCT00267527 and EudraCT 2005-003797-25]. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/91971820
[7] Memdouh, S., Gavrilović, I., Ng, K., Cowan, D., & Abbate, V. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis, 13(11–12), 1871–1887. https://doi.org/10.1002/dta.3183
[8] Timms, M., Ganio, K., & Steel, R. (2019). A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Testing and Analysis, 11(8), 1248–1257. https://doi.org/10.1002/dta.2599